Tizanidine Tablet
Product Images NDC 70518-4181

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 70518-4181). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

The image shows a medication label for tizanidine 4 mg tablets, oral use, supplied in a quantity of 90 tablets. The label includes the REMEDYREPACK INC. logo and identifies the lot number, expiration date, and barcode. It also states the drug is prescription only (RX) and provides storage instructions and repackaging information.*

FDA Label Image

Figure (C1813e2d 81a1 4db6 80a3 12c265d1e8f5 01)

Chemical structure of tizanidine hydrochloride, showing the arrangement of its chlorine, sulfur, nitrogen, and hydrogen atoms in the molecule's ring system.*

FDA Label Image

Figure (C1813e2d 81a1 4db6 80a3 12c265d1e8f5 02)

A pharmacokinetic graph showing plasma tizanidine concentration (ng/mL) over 24 hours after dosing with 2 x 4 mg tizanidine tablets or capsules. The lines compare concentrations with and without food intake, across four conditions: tablets with food, tablets without food, capsules with food, and capsules without food.*

FDA Label Image

Figure (C1813e2d 81a1 4db6 80a3 12c265d1e8f5 03)

A line graph showing improvement in Ashworth Score over time post-dose (0 to 6 hours) for 16 mg tizanidine, 8 mg tizanidine, and placebo. Both tizanidine doses show greater improvement than placebo, peaking around 2 hours, with error bars indicating variability.*

FDA Label Image

Figure (C1813e2d 81a1 4db6 80a3 12c265d1e8f5 04)

A line graph comparing improvement in Ashworth Score over time between tizanidine (mean dose 28.8 mg) and placebo groups. The x-axis shows time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint with Last Observation Carried Forward. The y-axis represents improvement in Ashworth Score, with negative values indicating improvement. The graph includes error bars for each data point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.